FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998045807> ?p ?o ?g. }

• W1998045807 endingPage "13" @default.
• W1998045807 startingPage "13" @default.
• W1998045807 abstract "Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center Mehran Afshar,1,* Jennifer Pascoe,1,2,* Sue Whitmarsh,1 Nicholas James,1,3 Emilio Porfiri1,2 1Queen Elizabeth Hospital Birmingham NHS Foundation Trust, 2Cancer Research UK Clinical Trials Unit, School of Cancer Sciences, University of Birmingham, Birmingham, UK; 3Cancer Research Unit, Clinical Trials Unit, University of Warwick, Coventry, UK *These authors have contribute equally to this work Aim: Temsirolimus has shown efficacy as first-line treatment of patients with metastatic renal cell carcinoma and poor prognostic features. The efficacy of temsirolimus in other clinical settings, such as second-line therapy, is unclear. The aim of this study was to investigate the outcomes of an unselected group of patients with renal cancer treated with temsirolimus in a compassionate use program. Patients and methods: This retrospective analysis included all patients receiving temsirolimus at a tertiary referral center between November 2007 and October 2008. Information was obtained through review of patient notes, electronic records, and pharmacy records. Baseline characteristics, prognostic features, and previous treatments were recorded for all patients. Outcome measures were response rate, progression-free survival (PFS), overall survival (OS), and toxicities. Results: Thirty-eight patients were included in the analysis, with median age of 62 years, among whom 37% were untreated and 63% had received one or more previous treatments. Thirty-four percent of the patients had three or more poor prognostic factors. Four patients (11%) achieved a partial response (PR); in all four of these patients, the PR was confirmed by two subsequent computed tomography (CT) scans, and in one patient, the PR lasted for more than 18 months. A total of 34% achieved stable disease, and 50% had disease progression. Median OS was 7.6 months (95% confidence interval [CI] 4.8–10.5), and median PFS was 3.2 months (95% CI 1.0–5.5). Patients with two or fewer poor prognostic factors had a survival of 10.12 months compared with 5.03 months of those with three or more. Median survival was 14.9 months for untreated patients and 6.4 months for previously treated patients. Conclusion: Our results indicate some efficacy of temsirolimus in untreated patients with renal tumors and poor-intermediate prognosis, although the limitations of small sample size and retrospective nature must be taken into account. The role of temsirolimus in previously treated patients remains controversial given the recently published results of the INTORSECT trial and the discrepancies between the few published series. Keywords: survival, renal cancer, toxicity, retrospective, tumor" @default.
• W1998045807 created "2016-06-24" @default.
• W1998045807 creator A5002598093 @default.
• W1998045807 creator A5022378006 @default.
• W1998045807 creator A5040405503 @default.
• W1998045807 creator A5073001920 @default.
• W1998045807 creator A5089769159 @default.
• W1998045807 date "2014-12-01" @default.
• W1998045807 modified "2023-09-25" @default.
• W1998045807 title "Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center" @default.
• W1998045807 cites W1568494625 @default.
• W1998045807 cites W2001112644 @default.
• W1998045807 cites W2058270864 @default.
• W1998045807 cites W2098176107 @default.
• W1998045807 cites W2103547328 @default.
• W1998045807 cites W2133742377 @default.
• W1998045807 cites W2139248078 @default.
• W1998045807 cites W2140885542 @default.
• W1998045807 cites W2144216815 @default.
• W1998045807 cites W2153867442 @default.
• W1998045807 cites W60461147 @default.
• W1998045807 doi "https://doi.org/10.2147/dddt.s73686" @default.
• W1998045807 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4277119" @default.
• W1998045807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25552898" @default.
• W1998045807 hasPublicationYear "2014" @default.
• W1998045807 type Work @default.
• W1998045807 sameAs 1998045807 @default.
• W1998045807 citedByCount "8" @default.
• W1998045807 countsByYear W19980458072015 @default.
• W1998045807 countsByYear W19980458072016 @default.
• W1998045807 countsByYear W19980458072017 @default.
• W1998045807 countsByYear W19980458072020 @default.
• W1998045807 crossrefType "journal-article" @default.
• W1998045807 hasAuthorship W1998045807A5002598093 @default.
• W1998045807 hasAuthorship W1998045807A5022378006 @default.
• W1998045807 hasAuthorship W1998045807A5040405503 @default.
• W1998045807 hasAuthorship W1998045807A5073001920 @default.
• W1998045807 hasAuthorship W1998045807A5089769159 @default.
• W1998045807 hasBestOaLocation W19980458071 @default.
• W1998045807 hasConcept C126322002 @default.
• W1998045807 hasConcept C143998085 @default.
• W1998045807 hasConcept C183713625 @default.
• W1998045807 hasConcept C185592680 @default.
• W1998045807 hasConcept C190283241 @default.
• W1998045807 hasConcept C2776135927 @default.
• W1998045807 hasConcept C2776820818 @default.
• W1998045807 hasConcept C2777472916 @default.
• W1998045807 hasConcept C512399662 @default.
• W1998045807 hasConcept C535046627 @default.
• W1998045807 hasConcept C55493867 @default.
• W1998045807 hasConcept C71924100 @default.
• W1998045807 hasConcept C75217442 @default.
• W1998045807 hasConceptScore W1998045807C126322002 @default.
• W1998045807 hasConceptScore W1998045807C143998085 @default.
• W1998045807 hasConceptScore W1998045807C183713625 @default.
• W1998045807 hasConceptScore W1998045807C185592680 @default.
• W1998045807 hasConceptScore W1998045807C190283241 @default.
• W1998045807 hasConceptScore W1998045807C2776135927 @default.
• W1998045807 hasConceptScore W1998045807C2776820818 @default.
• W1998045807 hasConceptScore W1998045807C2777472916 @default.
• W1998045807 hasConceptScore W1998045807C512399662 @default.
• W1998045807 hasConceptScore W1998045807C535046627 @default.
• W1998045807 hasConceptScore W1998045807C55493867 @default.
• W1998045807 hasConceptScore W1998045807C71924100 @default.
• W1998045807 hasConceptScore W1998045807C75217442 @default.
• W1998045807 hasLocation W19980458071 @default.
• W1998045807 hasLocation W19980458072 @default.
• W1998045807 hasLocation W19980458073 @default.
• W1998045807 hasLocation W19980458074 @default.
• W1998045807 hasLocation W19980458075 @default.
• W1998045807 hasOpenAccess W1998045807 @default.
• W1998045807 hasPrimaryLocation W19980458071 @default.
• W1998045807 hasRelatedWork W1551736161 @default.
• W1998045807 hasRelatedWork W1906318587 @default.
• W1998045807 hasRelatedWork W2053221007 @default.
• W1998045807 hasRelatedWork W2055195014 @default.
• W1998045807 hasRelatedWork W2099294889 @default.
• W1998045807 hasRelatedWork W2124315454 @default.
• W1998045807 hasRelatedWork W2138178078 @default.
• W1998045807 hasRelatedWork W2153867442 @default.
• W1998045807 hasRelatedWork W2154171266 @default.
• W1998045807 hasRelatedWork W2258391373 @default.
• W1998045807 isParatext "false" @default.
• W1998045807 isRetracted "false" @default.
• W1998045807 magId "1998045807" @default.
• W1998045807 workType "article" @default.